Ship of Theseus
Ship of Theseus is a therapeutics company pioneering the development of degradation-resistant biologics based on the homeobox (HOX) family of transcription factors. By making proprietary modifications to HOX proteins, the company overcomes natural cellular mechanisms that rapidly degrade these powerful regulators, enabling their use as pharmaceuticals with longer-lasting effects. Their mission is to unlock the therapeutic potential of HOX proteins for a range of indications, including chronic wounds, stem cell expansion, and more, by creating innovative biologics that can safely and effectively modulate cell behavior.
Ship of Theseus
What We Do
A pipeline of biologics based on modified HOX transcription factors, engineered to evade rapid intracellular degradation, enabling their use as long-acting therapeutics for various indications.
A lead candidate biologic designed to accelerate healing in chronic wounds, including diabetic and aged non-diabetic wounds, by leveraging the regenerative properties of HOXA3.
A biologic aimed at safely increasing stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant.
A diverse therapeutic pipeline targeting diabetic foot ulcers, neutropenia, psoriasis, androgenetic alopecia, fertility, and cancer using various modified HOX proteins.
Application Area
Regenerative Medicine
Drugs
Key People
Founding CEO
Advisor, Pipeline Development
Scientific Advisor, Protein and Plasmid Synthesis
Scientific Advisor, LEXE Modification Inventor
Scientific Advisor, HOXA3 diabetic wound expert
Senior Lead Accountant
News & Updates
Ship of Theseus won the European Wound Management Association (EWMA) Innovation Alliance competition for its HOXA3m in chronic wounds, surpassing 10 other elite applicants and gaining significant credibility and investor interest.
After a rigorous RFP process, Ship of Theseus engaged Charles River Laboratories for GMP manufacturing of its lead candidate for chronic wounds.
Awarded for preclinical development of a nuclear-targeting biologic to increase stem cell expansion and accelerate recovery from neutropenia after chemotherapy and bone marrow transplant.
Awarded for an approach that reprograms wound tissue to accelerate chronic wound healing in aging populations, demonstrating HOXA3+ superiority.
Awarded for stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant, demonstrating HOXB4+ superiority.
Ship of Theseus published research in Nature Scientific Reports demonstrating the benefits of HOXA3 in wound healing for both diabetic and non-diabetic mice.